Menu Search
Equities

Formycon AG

0W4N:LSE

Formycon AG

Actions
  • Price (EUR)47.10
  • Today's Change0.600 / 1.29%
  • Shares traded191.00
  • 1 Year change-23.66%
  • Beta--
Data delayed at least 20 minutes, as of Nov 22 2024 13:54 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Formycon AG is a Germany-based company engaged in providing biosimilar drugs and formulations. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The Company focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.

  • Revenue in EUR (TTM)60.80m
  • Net income in EUR63.90m
  • Incorporated2012
  • Employees239.00
  • Location
    Formycon AGFraunhoferstrasse 15MARTINSRIED 82152GermanyDEU
  • Phone+49 89 864667100
  • Fax+49 89 864667110
  • Websitehttps://www.formycon.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.